Cordycepin Remodels the Tumor Microenvironment of Colorectal Cancer by Down-regulating the Expression of PD-L1

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2023 Nov 1

PMID 37910234

Authors

Shaoxian Wu

Weiwei Fang

Lujun Chen

Chen Feng

Rongzhang Chen

Hanjie Ying

Xiao Zheng

Jingting Jiang

Affiliations

Soon will be listed here.

Abstract

Purpose: Colorectal cancer, as a common malignant tumor, poses a serious threat to human life. Cordycepin, derived from Cordyceps militaris extract, which was established as a capable inhibitor of tumor growth. Nevertheless, the precise antitumor mechanism of cordycepin in colorectal cancer cells remains elusive.

Methods: Herein, our initial focus was to explore the tumor-suppressive impact of cordycepin through its influence on various biological functions in murine colorectal cancer cells, conducted by an in vitro setting. First, we investigated the tumor-suppressive effect of cordycepin on the regulation of biological functions in murine colorectal cancer cells in vitro. Furthermore, we evaluated the in vivo antitumor potential of cordycepin using a mouse preclinical tumor model, and further explored the antitumor mechanism.

Results: Our findings revealed that cordycepin effectively inhibit the proliferation, invasion, and migration of murine colon cancer cells. Moreover, there is a substantial reduction in the expression of PD-L1 observed in tumor cells, in response to cordycepin treatment. Collectively, these results demonstrate the significant tumor-suppressive attributes of cordycepin against colorectal cancer. Consequently, our study lays a solid foundation for the potential clinical utilization of cordycepin in cancer therapy.

Conclusion: Cordycepin inhibits the biological functions of colorectal cancer cells and suppresses tumor growth by reducing the expression of PD-L1.

Citing Articles

Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.

Jiao J, Wu Y, Wu S, Jiang J Curr Treat Options Oncol. 2025; .

PMID: 40045029 DOI: 10.1007/s11864-025-01306-8.

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy.

Meyiah A, Khan F, Alfaki D, Murshed K, Raza A, Elkord E Transl Oncol. 2025; 53:102307.

PMID: 39904281 PMC: 11846588. DOI: 10.1016/j.tranon.2025.102307.

Cordycepin generally inhibits growth factor signal transduction in a systems pharmacology study.

Lawrence S, Lin J, Khurshid A, Utami W, Singhania R, Ashraf S FEBS Lett. 2024; 599(3):415-435.

PMID: 39508147 PMC: 11808429. DOI: 10.1002/1873-3468.15046.

Cordycepin Augments the Efficacy of Anti-PD1 against Colon Cancer.

Chang W, Chen Y, Lin C, Wang C, Shieh H, Chi C Biomedicines. 2024; 12(7).

PMID: 39062140 PMC: 11274779. DOI: 10.3390/biomedicines12071568.

Structural and pharmacological insights into cordycepin for neoplasms and metabolic disorders.

Zhang J, Yang Z, Zhao Z, Zhang N Front Pharmacol. 2024; 15:1367820.

PMID: 38953102 PMC: 11215060. DOI: 10.3389/fphar.2024.1367820.

References

AlMusawi S, Ahmed M, Nateri A . Understanding cell-cell communication and signaling in the colorectal cancer microenvironment. Clin Transl Med. 2021; 11(2):e308. PMC: 7868082. DOI: 10.1002/ctm2.308. View

Bray F, Parkin D . Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 2022; 23(6):719-728. DOI: 10.1016/S1470-2045(22)00270-4. View

Liao L, Chen C, Li N, Lin L, Huang B, Chang Y . Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci. 2020; 22(1). PMC: 7795419. DOI: 10.3390/ijms22010224. View

Chen Y, Huang H, Li Y, Xiao W, Liu Y, Chen R . TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. Front Immunol. 2022; 13:832230. PMC: 8935077. DOI: 10.3389/fimmu.2022.832230. View

CUNNINGHAM K, Manson W, SPRING F, Hutchinson S . Cordycepin, a metabolic product isolated from cultures of Cordyceps militaris (Linn.) Link. Nature. 1950; 166(4231):949. DOI: 10.1038/166949a0. View

Dai Y, Grant S . BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy. 2015; 11(2):416-8. PMC: 4502657. DOI: 10.1080/15548627.2014.998892. View

Deng Q, Li X, Fang C, Li X, Zhang J, Xi Q . Cordycepin enhances anti-tumor immunity in colon cancer by inhibiting phagocytosis immune checkpoint CD47 expression. Int Immunopharmacol. 2022; 107:108695. DOI: 10.1016/j.intimp.2022.108695. View

Doleschel D, Hoff S, Koletnik S, Rix A, Zopf D, Kiessling F . Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. J Exp Clin Cancer Res. 2021; 40(1):288. PMC: 8436536. DOI: 10.1186/s13046-021-02043-0. View

Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8(8):793-800. DOI: 10.1038/nm730. View

10.

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19):1789-1801. DOI: 10.1056/NEJMoa1802357. View

11.

Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X . Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021; 17(14):3837-3849. PMC: 8495390. DOI: 10.7150/ijbs.64077. View

12.

Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X . IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 2018; 143(4):931-943. DOI: 10.1002/ijc.31357. View

13.

Garcia-Diaz A, Shin D, Moreno B, Saco J, Escuin-Ordinas H, Rodriguez G . Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017; 19(6):1189-1201. PMC: 6420824. DOI: 10.1016/j.celrep.2017.04.031. View

14.

Hawley S, Ross F, Russell F, Atrih A, Lamont D, Grahame Hardie D . Mechanism of Activation of AMPK by Cordycepin. Cell Chem Biol. 2020; 27(2):214-222.e4. PMC: 7031697. DOI: 10.1016/j.chembiol.2020.01.004. View

15.

Jang H, Yang K, Hwang I, Huh Y, Kim D, Yoo H . Cordycepin inhibits human ovarian cancer by inducing autophagy and apoptosis through Dickkopf-related protein 1/β-catenin signaling. Am J Transl Res. 2019; 11(11):6890-6906. PMC: 6895532. View

16.

Jeong M, Lee C, Lee S, Seo S, Seo M, Kang B . Cordycepin-enriched Cordyceps militaris induces immunomodulation and tumor growth delay in mouse-derived breast cancer. Oncol Rep. 2013; 30(4):1996-2002. DOI: 10.3892/or.2013.2660. View

17.

Jeong J, Park C, Cha H, Hong S, Park S, Kim G . Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4. BMB Rep. 2018; 51(10):532-537. PMC: 6235086. View

18.

Pietras P, Lesniczak-Staszak M, Kasprzak A, Andrzejewska M, Jopek K, Sowinski M . MVP Expression Facilitates Tumor Cell Proliferation and Migration Supporting the Metastasis of Colorectal Cancer Cells. Int J Mol Sci. 2021; 22(22). PMC: 8623820. DOI: 10.3390/ijms222212121. View

19.

Kratzer T, Jemal A, Miller K, Nash S, Wiggins C, Redwood D . Cancer statistics for American Indian and Alaska Native individuals, 2022: Including increasing disparities in early onset colorectal cancer. CA Cancer J Clin. 2022; 73(2):120-146. DOI: 10.3322/caac.21757. View

20.

Lee C, Huang K, Shaw J, Chen J, Kuo W, Shen G . Trends in the Immunomodulatory Effects of : Total Extracts, Polysaccharides and Cordycepin. Front Pharmacol. 2020; 11:575704. PMC: 7735063. DOI: 10.3389/fphar.2020.575704. View